Skip to main content
. Author manuscript; available in PMC: 2017 Dec 19.
Published in final edited form as: Clin Cancer Res. 2016 Jun 29;23(1):124–136. doi: 10.1158/1078-0432.CCR-15-1535

Figure 4.

Figure 4

Immune analysis. A, CD8 effector to FoxP3+ T regulatory cell ratios are highest in treatment arms that include anti-PD-1. B, Dual checkpoint blockade and triple therapy show a trend toward the lowest percentage of FoxP3+ CD4 T cells. Triple therapy shows a trend toward highest mono- and polyclonal cytokine production by CD4 (C) and CD8 (D) T cells compared with all the other arms. Immune profiling experiments were repeated in duplicates with ≥3 mice per arm (A–D). E, CD4 T-cell depletion abrogated the treatment effect of anti-TIM-3 + SRS with no significant difference in survival between the TIM-3 only and TIM-3 + SRS(-CD4) arms. CD8 depletion [TIM-3 +SRS(-CD4)] also resulted in diminished treatment effect (0% OS) but had significantly improved survival compared with animals treated with anti-TIM-3 alone with median survival of 31.5 and 20.5 days, respectively (P < 0.001). F, CD4 and CD8 depletion also abrogated the survival benefits of triple therapy (0% OS), with median survival of 25.0 and 38.0 days, respectively. Depletion experiment was repeated in duplicate, and a representative repeat was presented, n = 8. Survival was analyzed by Kaplan–Meier method and compared by log-rank Mantel–Cox test. *, P < 0.05.